SMS Pharmaceuticals Ltd (SMSPHARMA) — shareholding pattern, promoter holding, financials and share price
About SMS Pharmaceuticals Ltd (SMSPHARMA)
SMS Pharmaceuticals Ltd operates in the Pharmaceuticals industry, within the Healthcare sector. It trades on the NSE as SMSPHARMA and on the BSE under scrip code 532815. Its ISIN is INE812G01025.
SMS Pharmaceuticals Ltd is a diversified and integrated pharmaceutical company with interests in Active Pharmaceutical Ingredients (API) and Intermediates. [1]
SMS Pharmaceuticals Limited manufactures Active Pharma Ingredients (APIs) and intermediates, with multiple FDA-compliant facilities in Hyderabad and Andhra Pradesh. The company is a leader in the production of APIs and leverages its extensive R&D capabilities to maintain its market position.
The company reported an 80% year-on-year increase in profit after tax for Q2 FY26, driven by a strategic focus on backward integration and volume growth across key APIs.
Listed peers in Pharmaceuticals: Gujarat Themis Biosyn Ltd, Gufic BioSciences Ltd, Novartis India Ltd, Aarti Drugs Ltd, Morepen Laboratories Ltd, Panacea Biotec Ltd.
Valuation & Returns
10 Jul 2026At ₹401.85 a share on 10 Jul 2026, SMS Pharmaceuticals Ltd (SMSPHARMA) was valued at a price-to-earnings ratio of 42.77x against an industry P/E of 36.41x and a price-to-book of 5.88x on a book value of ₹68.3 per share as of Mar 2025. Solomo computes return on equity of 13.76% and return on capital employed of 14.7% from filed results. Earnings ratios use consolidated results for the twelve months Jun 2025 to Mar 2026.
- P/E
- 42.77x
- Industry P/E
- 36.41x
- P/B
- 5.88x
- EPS (TTM)
- ₹9.4
- Book value / share
- ₹68.3
- ROE
- 13.76%
- ROCE
- 14.7%
- ROA
- 7.63%
- Debt / equity
- 0.49x
- Dividend yield
- 0.1%
- EBITDA margin
- 20.25%
- 52-week range
- ₹208.2 – ₹446.5
Ratios are computed from filed results and the last recorded price. Not investment advice.
Financial Performance
Mar 2026In the year ended Mar 2026, SMS Pharmaceuticals Ltd (SMSPHARMA) reported revenue of ₹887 crore, net profit of ₹102 crore and earnings per share of ₹10.89. That compares with revenue of ₹783 crore and net profit of ₹69 crore in Mar 2025. Figures are consolidated, as filed with the exchanges.
In the quarter ended Mar 2026, revenue was ₹238 crore and net profit ₹33 crore (consolidated).
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue (₹ cr) | 520 | 522 | 709 | 783 | 887 |
| Net profit (₹ cr) | 62 | -7 | 50 | 69 | 102 |
| EPS (₹) | 7.35 | -0.83 | 5.88 | 7.8 | 10.89 |
| Measure | 10Y | 5Y | 3Y | 1Y |
|---|---|---|---|---|
| Sales growth | 3.35% | 13.01% | 14.59% | 10.36% |
| Profit growth | 5.67% | 15.91% | 0.17% | 36.99% |
| Stock price CAGR | 17% | 16% | 56% | 58% |
Ownership Summary
Jun 2026As of Jun 2026, promoters hold 68.07% of SMS Pharmaceuticals Ltd (SMSPHARMA) (unchanged from the previous quarter), foreign institutional investors (FII) hold 0.65% and domestic institutional investors (DII) hold 2.83%. Promoters have pledged 18% of their holding. Market capitalisation was ₹3,763 crore on 10 Jul 2026. Shareholding is filed quarterly with BSE and NSE; Solomo carries every filing back to Sep 2010.
Largest disclosed public shareholders in Jun 2026: QUANT MUTUAL FUND - QUANT SMALL CAP FUND 2.81%, ANIRUDDH MUNDRA 2.01%, Venkata Subbaraju Penmatsa HUF 1.82%, SUDEEPTHI GOPINEEDI 1.41%, VENKATA PRAVEEN TALLURI 1.41%. Only stakes above the 1% disclosure threshold are named in filings.
| Quarter | Promoter | Pledged | FII | DII | Public |
|---|---|---|---|---|---|
| Jun 2026 | 68.07% | 18% | 0.65% | 2.83% | 31.93% |
| Mar 2026 | 68.07% | 18% | 0.31% | 3.02% | 31.93% |
| Dec 2025 | 68.07% | 18% | 0.04% | 3.21% | 31.93% |
| Sep 2025 | 68.07% | 34.6% | 0.28% | 2.88% | 31.93% |
| Jun 2025 | 68.07% | 34.6% | 0.17% | 2.88% | 31.93% |
| Mar 2025 | 66.26% | 37.6% | 0.08% | 2.43% | 33.74% |
| Dec 2024 | 64.67% | 19.4% | 0.31% | 2.55% | 35.33% |
| Sep 2024 | 64.67% | 19.4% | 0.52% | 2.55% | 35.33% |